No Data
No Data
Sansheng Guojian (688336): The first quarterly report exceeded expectations, basic business is steady, and the follow-up self-exemption pipeline is progressing at an accelerated pace
The company released its quarterly report, with 24Q1 revenue of 267 million yuan, yoy +28.7%; net profit to mother was 91 million yuan, +172% over the same period last year, slightly exceeding expectations. The growth rate of the 3 old products is stable. The source of growth is (1) Exipp precharge
Sansheng Guojian (688336): Performance exceeds expectations, core product revenue continues to grow at a high rate
Guide to this report: The company released its 2024 quarterly report. The performance exceeded expectations, the core products were rapidly released, and the cost reduction and efficiency effects were obvious. Revenue and profit are expected to grow steadily throughout the year; the research pipeline is progressing steadily, which is expected to contribute to the increase in performance in the future.
Sansheng Guojian (688336): The beautiful start of the year is expected to continue to be rich in self-exemption pipelines
1Q24 revenue increased 29% year-on-year, with a sharp increase after deducting non-net profit. The company announced 1Q24's operating income of 270 million yuan (+29% yoy), net profit to mother of 90 million yuan (+172% yoy), and zero deducted non-net profit.
The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.
The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.
Revenue from main products such as Genipip surged, and the net profit of Sansheng Guojian (688336.SH) surged 171.88% in the first quarter to 91.191,000 yuan
Sansheng Guojian (688336.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 267 million yuan, an increase of 28.72%; net profit attributable to shareholders of listed companies was 911.191,000 yuan, a year-on-year increase of 171.88%; net profit attributable to shareholders of listed companies deducted non-recurring profit and loss of 857.583 million yuan, a year-on-year increase of 203.60%; basic earnings per share were 0.15 yuan/share.
Sansheng Guojian (688336.SH): Non-net profit of 857.583 million yuan in the first quarter increased 203.6% year over year
Gelonghui, April 25 | Sansheng Guojian (688336.SH) released its first quarter report. Operating revenue was 267 million yuan, up 28.72% year on year, net profit of 911.191,000 yuan, up 171.88% year on year, after deducting non-net profit of 857.583 million yuan, up 203.6% year on year, with basic earnings of 0.15 yuan per share.
No Data